100 Participants Needed

Light + Negative Ion Therapy for Depression

VE
RC
RL
RW
Overseen ByRaymond W Lam, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of British Columbia
Must be taking: Antidepressants
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to explore whether light therapy or negative ion therapy can help people with major depressive disorder (MDD) maintain symptom remission after stopping antidepressants. Researchers will monitor participants for relapse as they gradually discontinue their current medication. The study involves using light therapy or negative ion therapy devices for 30 minutes each morning. Individuals with MDD who are currently in remission with antidepressants and wish to stop due to side effects might be a good fit for this study. As an unphased trial, this study offers a unique opportunity to explore alternative therapies for maintaining remission in MDD.

Will I have to stop taking my current medications?

Yes, participants will need to slowly stop taking their current antidepressant medication during the study while using light or negative ion therapy.

What prior data suggests that light therapy and negative ion therapy are safe for treating depression?

Research shows that both light therapy and negative ion therapy are generally safe. Studies have found light therapy to be well-tolerated, with no serious side effects. Most reactions, such as slight eye strain or headaches, are minor and temporary, resolving quickly.

Negative ion therapy has shown mixed results for treating depression, but studies have not identified any major safety concerns. Research even suggests potential health benefits, such as reducing inflammation.

Overall, both treatments have been used safely in past studies. However, this trial specifically examines their use for individuals discontinuing antidepressants. Always consult a healthcare provider for personalized advice.12345

Why are researchers excited about this trial?

Researchers are excited about light and negative ion therapies for depression because they offer novel approaches that differ significantly from traditional treatments like antidepressants and psychotherapy. Unlike medications, which often take weeks to show effectiveness, these therapies have the potential to provide quicker mood improvements by influencing the brain's chemistry through non-invasive means. Light therapy uses bright light exposure to regulate circadian rhythms and boost mood, while negative ion therapy increases exposure to high-density ions that may enhance serotonin levels naturally. These treatments could represent a promising alternative for those seeking options without the side effects typically associated with antidepressants.

What evidence suggests that this trial's treatments could be effective for depression?

This trial will compare the effects of negative ion therapy and light therapy for depression. Research has shown that negative ion therapy, one of the treatments in this trial, can help reduce symptoms of depression. Studies found that exposure to a high number of negative air ions lowered depression scores, especially with increased exposure. Light therapy, another treatment option in this trial, also shows promise for treating depression. A review of several studies showed that bright light therapy effectively reduced symptoms of major depressive disorder (MDD). Both treatments offer potential non-medication options for managing MDD.12367

Who Is on the Research Team?

RW

Raymond W Lam, MD

Principal Investigator

University of British Columbia

Are You a Good Fit for This Trial?

This trial is for adults with recurrent major depressive disorder (MDD) who are in remission thanks to antidepressants and want to stop their medication due to side effects or other reasons. They must meet specific criteria, have been on a stable dose of antidepressants, and be willing to do self-reports in English or French. People with significant personality disorders, high suicide risk, recent substance abuse, severe medical conditions, history of bad reactions when stopping antidepressants, eye conditions that limit light therapy use, or those using certain medications can't join.

Inclusion Criteria

I want to stop my antidepressant due to side effects or other reasons.
I am in remission from depression, with low scores on a depression scale.
I can complete surveys and online tasks in English or French.
See 2 more

Exclusion Criteria

I am continuing with my current depression treatment.
My main mental health condition is major depressive disorder, not bipolar disorder.
I use medication for mental health that isn't an antidepressant or benzodiazepine.
See 9 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive light therapy or negative ion therapy while tapering off antidepressants

28 weeks
Bi-weekly visits until week 8, then every 4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 weeks
Final observational visit by Zoom at Week 52

What Are the Treatments Tested in This Trial?

Interventions

  • Light therapy
  • Negative ion therapy
Trial Overview The LIMIT-D study is exploring if negative ion therapy and light therapy can help prevent depression from coming back after stopping antidepressants. It's a preliminary test involving 100 participants over 28 weeks where half will receive active treatments and the other half inactive ones as they gradually stop taking their medication.
How Is the Trial Designed?
2Treatment groups
Active Control
Group I: Negative ion therapyActive Control1 Intervention
Group II: Light therapyActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of British Columbia

Lead Sponsor

Trials
1,506
Recruited
2,528,000+

Ontario Brain Institute

Collaborator

Trials
12
Recruited
3,000+

Centre for Addiction and Mental Health

Collaborator

Trials
388
Recruited
84,200+

University of Toronto

Collaborator

Trials
739
Recruited
1,125,000+

Université de Montréal

Collaborator

Trials
223
Recruited
104,000+

Canadian Institutes of Health Research (CIHR)

Collaborator

Trials
1,417
Recruited
26,550,000+

McMaster University

Collaborator

Trials
936
Recruited
2,630,000+

Published Research Related to This Trial

In a study of 25 subjects with seasonal affective disorder, high-density negative ion treatment (2.7 x 10(6) ions/cm3) significantly reduced depressive symptoms, with 58% of participants showing a 50% or greater reduction in symptoms compared to only 15% with low-density treatment.
The high-density negative ion treatment was found to be safe, with no reported side effects, and may serve as an effective alternative or supplement to traditional light therapy and medications for managing seasonal affective disorder.
Treatment of seasonal affective disorder with a high-output negative ionizer.Terman, M., Terman, JS.[2007]
A review of 33 studies involving human participants found that negative air ionization is significantly associated with lower depression ratings, especially at high exposure levels, suggesting a potential therapeutic effect for individuals with depression.
However, the study did not find consistent effects of air ionization on anxiety, mood, relaxation, or personal comfort, indicating that while negative ions may help with depression, their overall impact on other psychological measures remains unclear.
Air ions and mood outcomes: a review and meta-analysis.Perez, V., Alexander, DD., Bailey, WH.[2021]
A review of 62 studies on the effects of air ions on health found no consistent evidence of beneficial or adverse effects in laboratory animals, indicating that exposure to positive or negative air ions does not significantly impact health outcomes.
The highest quality studies showed no effects on various health measures, and there were no clear dose-response relationships, suggesting that air ion exposure lacks a reliable biological mechanism for interaction with health.
Exposure of laboratory animals to small air ions: a systematic review of biological and behavioral studies.Bailey, WH., Williams, AL., Leonhard, MJ.[2018]

Citations

Bright Light Therapy: Growing Evidence Beyond Seasonal ...... late 2024, found that bright light therapy was an effective supplementary treatment for depressive disorders other than seasonal depression.
The Use of Phototherapy for the Treatment of Non ...A systematic review of light therapy on mood scores in major depressive disorder: light specification, dose, timing and delivery. Non-seasonal ...
Effectiveness of bright light therapy in patients suffering ...Background and objectives. Depressive disorders, both unipolar (MDD) and bipolar (BD), impact patients and society greatly. In bipolar depression and seasonal ...
4.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/39657294
Efficacy of bright light therapy improves outcomes ...Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310013, China.
The effect of bright light therapy on major depressive disorderThis meta-analysis offers positive evidence that favours BLT in alleviating depressive symptoms in MDD, suggesting that it could be a convenient and easily ...
6.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/31917880/
Efficacy and safety of bright light therapy for manic and ...This systematic review and meta-analysis evaluated whether bright light therapy (BLT) is an effective and safe treatment for manic/depressive symptoms
Bright Light Therapy as Add-On to Inpatient Treatment in ...This randomized clinical trial evaluates bright light therapy vs treatment as usual for youth with depression.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security